Exacerbation of dideoxycytidine-induced neuropathy with dideoxyinosine.
Dideoxycytidine (ddC) and dideoxyinosine (ddI) are nucleoside derivatives that exhibit antiretroviral activity against the human immunodeficiency virus (HIV). Both of these agents are under active investigation as potential therapies for patients with HIV infection. In addition, both drugs may be obtained for HIV-infected individuals who cannot tolerate zidovudine. A major focus of the research effort involving these agents has been to define their toxicities. Both agents may cause peripheral neuropathy. We wish to report a patient who developed severe neuropathy following the administration of ddI that was given shortly after the patient was removed from a clinical trial of ddI. The rapid development of toxicity indicates that this side effect is additive or synergistic for these agents.
LeLacheur
S F
SF
Department of Medicine, George Washington University, Washington, D.C.
Simon
G L
GL
D016263:AIDS-Associated Nephropathy / Q000139:chemically induced* / Q000382:microbiology; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D016049:Didanosine / Q000009:adverse effects*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D016047:Zalcitabine / Q000009:adverse effects*
D000998:Antiviral Agents; D016047:Zalcitabine; D016049:Didanosine